{"id":"NCT02648217","sponsor":"Novo Nordisk A/S","briefTitle":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan","officialTitle":"A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-04","primaryCompletion":"2016-09-04","completion":"2016-09-05","firstPosted":"2016-01-06","resultsPosted":"2018-09-11","lastUpdate":"2018-09-11"},"enrollment":263,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec/insulin aspart","otherNames":[]},{"type":"DRUG","name":"biphasic insulin aspart","otherNames":[]}],"arms":[{"label":"IDegAsp U100 BID","type":"EXPERIMENTAL"},{"label":"BIAsp U100 BID","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Africa and Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus before, during and after Ramadan.","primaryOutcome":{"measure":"Change in HbA1c (%) (Glycosylated Haemoglobin)","timeFrame":"From week 0 to end of Ramadan (day 29 of Ramadan)","effectByArm":[{"arm":"Insulin Degludec/Insulin Aspart","deltaMin":-1.11,"sd":0.13},{"arm":"Biphasic Insulin Aspart 30","deltaMin":-1.13,"sd":0.13}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8426"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":1},"locations":{"siteCount":32,"countries":["Algeria","India","Lebanon","Malaysia","South Africa","United Arab Emirates"]},"refs":{"pmids":["29183844","37435938","35044568"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":130},"commonTop":["Blood glucose decreased","Pyrexia","Upper respiratory tract infection"]}}